Literature DB >> 7897404

Neuroleptic malignant syndrome.

P F Buckley, M Hutchinson.   

Abstract

Entities:  

Mesh：

Year:  1995        PMID： 7897404      PMCID： PMC1073359          DOI： 10.1136/jnnp.58.3.271

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  46 in total

Review 1.  Neuroleptic-induced catatonia as a stage in the progression toward neuroleptic malignant syndrome.

Authors:  M M Woodbury; M A Woodbury
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1992-11       Impact factor: 8.829

2.  A prospective analysis of 24 episodes of neuroleptic malignant syndrome.

Authors:  P Rosebush; T Stewart
Journal:  Am J Psychiatry       Date:  1989-06       Impact factor: 18.112

3.  Risk factors for neuroleptic malignant syndrome. A case-control study.

Authors:  P E Keck; H G Pope; B M Cohen; S L McElroy; A A Nierenberg
Journal:  Arch Gen Psychiatry       Date:  1989-10

4.  Neuroleptic-induced extrapyramidal symptoms with fever. Heterogeneity of the 'neuroleptic malignant syndrome'.

Authors:  D F Levinson; G M Simpson
Journal:  Arch Gen Psychiatry       Date:  1986-09

5.  Ecstasy, the serotonin syndrome, and neuroleptic malignant syndrome--a possible link?

Authors:  D Ames; W C Wirshing
Journal:  JAMA       Date:  1993-02-17       Impact factor: 56.272

6.  Electroconvulsive Therapy in the Treatment of the Neuroleptic Malignant Syndrome.

Authors:  John M. Davis; Philip G. Janicak; Paul Sakkas; Cindy Gilmore; Zhengyu Wang
Journal:  Convuls Ther       Date:  1991

7.  Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade?

Authors:  V W Henderson; G F Wooten
Journal:  Neurology       Date:  1981-02       Impact factor: 9.910

8.  A successful electroconvulsive treatment of neuroleptic malignant syndrome.

Authors:  H Hermesh; D Aizenberg; A Weizman
Journal:  Acta Psychiatr Scand       Date:  1987-03       Impact factor: 6.392

9.  A comparison of diagnostic criteria for neuroleptic malignant syndrome.

Authors:  R J Gurrera; S S Chang; J A Romero
Journal:  J Clin Psychiatry       Date:  1992-02       Impact factor: 4.384

10.  Spectrum concept of neuroleptic malignant syndrome.

Authors:  S Singh; G Singh; S Ong
Journal:  Br J Psychiatry       Date:  1988-07       Impact factor: 9.319
View more
  14 in total

1.  The use of clonidine in the management of autonomic overactivity in neuroleptic malignant syndrome.

Authors:  L Gregorakos; T Thomaides; S Stratouli; E Sakayanni
Journal:  Clin Auton Res       Date:  2000-08       Impact factor: 4.435

2.  Cerebellar gait ataxia following neuroleptic malignant syndrome.

Authors:  M Manto; S Goldman; J Hildebrand
Journal:  J Neurol       Date:  1996-01       Impact factor: 4.849

3.  Schizophrenia and anaesthesia.

Authors:  Liew Sat Lin Constance; Meryl Grace Lansing; Foo Kiang Khor; Rajesh Kumar Muniandy
Journal:  BMJ Case Rep       Date:  2017-11-23

Review 4.  Neuroleptic malignant syndrome in the acquired immunodeficiency syndrome.

Authors:  J L Hernández; L Palacios-Araus; S Echevarría; A Herrán; J F Campo; J A Riancho
Journal:  Postgrad Med J       Date:  1997-12       Impact factor: 2.401

5.  Cerebellar degeneration following neuroleptic malignant syndrome.

Authors:  V Lal; V Sardana; A Thussu; I M Sawhney; S Prabhakar
Journal:  Postgrad Med J       Date:  1997-11       Impact factor: 2.401

Review 6.  [Rhabdomyolysis and myoglobinuria].

Authors:  A Lindner; S Zierz
Journal:  Nervenarzt       Date:  2003-05-14       Impact factor: 1.214

Review 7.  The neuroleptic malignant syndrome: a logical approach to the patient with temperature and rigidity.

Authors:  M V Balzan
Journal:  Postgrad Med J       Date:  1998-02       Impact factor: 2.401

8.  Neuroleptic malignant syndrome: a review for neurohospitalists.

Authors:  Brian D Berman
Journal:  Neurohospitalist       Date:  2011-01

Review 9.  Antipsychotic dose escalation as a trigger for neuroleptic malignant syndrome (NMS): literature review and case series report.

Authors:  Julie Langan; Daniel Martin; Polash Shajahan; Daniel J Smith
Journal:  BMC Psychiatry       Date:  2012-11-29       Impact factor: 3.630

10.  Temporal changes in serum creatine kinase concentration and degree of muscle rigidity in 24 patients with neuroleptic malignant syndrome.

Authors:  Koichi Nisijima; Katutoshi Shioda
Journal:  Neuropsychiatr Dis Treat       Date:  2013-06-18       Impact factor: 2.570
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.